Associated Papers
Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies.
Tagawa K et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
30206299 (PubMed )
Supplement: 41397_2018_44_MOESM5_ESM.xlsx › Sheet1
Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).
Strassburg CP et al.
Critical Reviews in Clinical Laboratory Sciences, 2008
Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
Nagar S et al.
Oncogene, 2006
Amino acid residue ILE211 is essential for the enzymatic activity of human UDP-glucuronosyltransferase 1A10 (UGT1A10).
Martineau I et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2004
Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10.
Jinno H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2003
Three novel single nucleotide polymorphisms in UGT1A10.
Saeki M et al.
Drug Metabolism and Pharmacokinetics, 2002
Select a paper to view details